BiotechTube

JDQ443 + trametinib + Ribociclib + cetuximab

Phase 1/2Active
0 views this week 0 watching💤 Quiet
Interest: 36/100
36
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

KRAS G12C Mutant Solid Tumors

Conditions

KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small Cell Lung, Carcinoma, Non-Small-Cell Lung, Non-Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma, Nonsmall Cell Lung Cancer, Colorectal Cancer, Colorectal Carcinoma, Colorectal Neoplasms, Colorectal Tumors, Neoplasms, Colorectal

Trial Timeline

Oct 24, 2022 → Nov 30, 2026

NCT ID
NCT05358249

About JDQ443 + trametinib + Ribociclib + cetuximab

JDQ443 + trametinib + Ribociclib + cetuximab is a phase 1/2 stage product being developed by Novartis for KRAS G12C Mutant Solid Tumors. The current trial status is active. This product is registered under clinical trial identifier NCT05358249. Target conditions include KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small Cell Lung, Carcinoma, Non-Small-Cell Lung.

What happened to similar drugs?

0 of 2 similar drugs in KRAS G12C Mutant Solid Tumors were approved

Approved (0) Terminated (0) Active (2)
🔄HRS-4642 + AG + HRS-4642 placebo + AGJiangsu Hengrui MedicinePhase 3
🔄AMG 510 + DocetaxelAmgenPhase 3

Hype Score Breakdown

Clinical
9
Activity
12
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05358249Phase 1/2Active

Competing Products

20 competing products in KRAS G12C Mutant Solid Tumors

See all competitors
ProductCompanyStageHype Score
HRS-4642 + Adebrelimab + SHR-9839 + Pemetrexed Disodium for Injection、Cisplatin Injection、Carboplatin for Injection + Cetuximab Solution for InfusionJiangsu Hengrui MedicinePhase 1/2
36
HRS-6093Jiangsu Hengrui MedicinePhase 1
36
HRS-4642Jiangsu Hengrui MedicinePhase 1
33
HRS-4642 + AG + HRS-4642 placebo + AGJiangsu Hengrui MedicinePhase 3
47
Pembrolizumab + TrametinibMerckPhase 1
29
Opnurasib + TNO155 + trametinib + cetuximab + tislelizumabNovartisPhase 1/2
39
JDQ443 + TNO155 + tislelizumabNovartisPhase 1/2
36
JDQ443NovartisPhase 2
39
Trametinib + Anlotinib + TislelizumabNovartisPhase 1/2
39
AMG 510AmgenPhase 1
33
AMG 510 + DocetaxelAmgenPhase 3
44
Epirubicine, Oxaliplatin, Capecitabine, PanitumumabAmgenPhase 2
27
AMG 410 + Pembrolizumab + PanitumumabAmgenPhase 1
36
sotorasib + Anti PD-1/L1 + MidazolamAmgenPhase 1/2
36
MEK162 and mFOLFIRIPfizerPhase 1
29
IBI351+AK112Innovent BiologicsPhase 2
42
GFH925Innovent BiologicsPhase 1/2
32
Momelotinib (MMB) + TrametinibGSK plcPhase 1
21
BAY3498264BayerPhase 1
33
ARV-806ArvinasPhase 1/2
33